

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT						
NATURE OF CONVEYANCE:	ASSIGNMENT						
CONVEYING PARTY DATA							
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Francis S. Collins</td> <td>05/24/2006</td> </tr> <tr> <td>Brian C. Capell</td> <td>05/24/2006</td> </tr> </tbody> </table>		Name	Execution Date	Francis S. Collins	05/24/2006	Brian C. Capell	05/24/2006
Name	Execution Date						
Francis S. Collins	05/24/2006						
Brian C. Capell	05/24/2006						
RECEIVING PARTY DATA							
Name:	The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services						
Street Address:	6011 Executive Blvd., Suite 325						
Internal Address:	Office of Technology Transfer, National Institutes of Health						
City:	Rockville						
State/Country:	MARYLAND						
Postal Code:	20852						
PROPERTY NUMBERS Total: 1							
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>13567432</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	13567432		
Property Type	Number						
Application Number:	13567432						
CORRESPONDENCE DATA							
Fax Number:	5035955301						
Phone:	(503) 595-5300						
Email:	tanya.harding@klarquist.com						
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>							
Correspondent Name:	Tanya M. Harding, Ph.D.						
Address Line 1:	121 SW Salmon Street, Suite 1600						
Address Line 2:	One World Trade Center, Suite 1600						
Address Line 4:	Portland, OREGON 97204						
ATTORNEY DOCKET NUMBER:	8596-86930-02 TMH						
NAME OF SUBMITTER:	Tanya M. Harding, Ph.D.						
Total Attachments: 2 source=8593002_Assignment2NIH#page1.tif source=8593002_Assignment2NIH#page2.tif							

CH \$40.00 13567432

WDN/TMH:mlb 4239-69982-03 E-055-2005/2-PCT-01 05/23/06

ASSIGNMENT

We, Francis S. Collins, of 5908 Tudor Lane, Rockville, Maryland 20852, a citizen of the United States of America, and Brian C. Capell, of 7 Sailors Way, Rumson, New Jersey 07760, a citizen of the United States of America, have invented with others, a certain invention entitled FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING AND ATHEROSCLEROSIS for which the following patent applications have been filed:

U.S. Provisional Patent Application No. 60/648,307, filed on January 28, 2005;
U.S. Provisional Patent Application No. 60/707,192, filed on August 9, 2005; and
PCT Application No. PCT/US2006/002977, filed on January 27, 2006; and

all of which applications are collectively referred to herein as "the patent applications."

We were employed by the Department of Health and Human Services at the time the invention was made. The conditions under which said invention was made are such as to entitle the Government of the United States of America under Paragraph 1(a) of Executive Order 10096, to the entire right, title, and interest in the invention, in the United States and all other countries throughout the world.

In consideration of our obligations under Executive Order 10096, and other valuable consideration, we the undersigned, have sold, assigned, and transferred and do sell, assign, and transfer to The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (hereinafter THE GOVERNMENT), and successors and assigns, the full and exclusive right, title, and interest in the patent applications and invention throughout the United States of America, its territories and dependencies, and all other countries. This includes an assignment of all Letters Patent that may be granted on the invention in the United States of America and all countries throughout the world, and any divisional, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof; and the right to claim priority from the patent applications as provided for by United States law, the Patent Cooperation Treaty, the European Patent Convention, the Paris Convention, or other applicable law.

We authorize and request the issuance of said Letters Patent to THE GOVERNMENT as assignee of the entire right, title, and interest to be held as fully and entirely as the same would have been held by us had this assignment not been made.

We warrant that there are no outstanding assignments, grants, liens, encumbrances, or agreements either written, oral, or implied that will impair, diminish, limit, or abridge the interest herein conveyed at the time of the execution of the present assignment.

We also agree upon reasonable request to communicate to THE GOVERNMENT, its representatives, assigns or agents, any facts known to us respecting the invention, and testify in any legal proceedings, sign all lawful papers, execute all divisional, continuing and reissue applications, make all rightful oaths, provide all requested documents, and do everything reasonably possible to aid THE GOVERNMENT and its assigns to obtain and enforce proper patent protection for the invention in the United States or any foreign country. These provisions are binding upon our heirs, legal representatives, administrators and assigns.

We have authorized THE GOVERNMENT to file and prosecute the patent applications, as well as any corresponding international or national applications that claim priority from them. THE GOVERNMENT has the right to select attorneys or agents of its choice to prosecute at its discretion the patent applications on its behalf.

